Latest Ratios: P/E Ratio -4.4x · EV/EBITDA N/A · ROE -383.1%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $154M | $51M | $198M | $151M | $97M | $145M | $2.0B | — | — |
| Enterprise Value | $207M | $105M | $234M | $185M | $86M | $122M | $1.9B | — | — |
| P/E Ratio → | -4.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.74 | 0.58 | 2.78 | 3.08 | 2.53 | 2.66 | 42.82 | — | — |
| P/B Ratio | — | — | 9.50 | 32.99 | 4.70 | 7.34 | 47.39 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.19 | 3.28 | 3.78 | 2.24 | 2.24 | 42.06 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.2% | 75.2% | 78.2% | 73.5% | 63.0% | 44.0% | 51.7% | 75.3% | 78.4% |
| Operating Margin | -31.5% | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% | -50.3% | -108.9% | -114.8% |
| Net Profit Margin | -39.8% | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% | -68.8% | -125.1% | -128.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -383.1% | -383.1% | -337.3% | -414.1% | -324.5% | -141.8% | -76.2% | — | — |
| ROA | -38.2% | -38.2% | -43.7% | -54.3% | -77.5% | -43.8% | -38.5% | -76.2% | -67.0% |
| ROIC | -38.7% | -38.7% | -54.1% | -128.2% | -1186.6% | -1602.1% | — | — | — |
| ROCE | -36.4% | -36.4% | -46.4% | -60.9% | -86.3% | -60.2% | -42.5% | -99.7% | -67.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 2.97 | 13.25 | 1.55 | 0.51 | 0.67 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 1.71 | 7.51 | -0.55 | -1.15 | -0.83 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.57 | -3.57 | -4.20 | -4.47 | -7.11 | -8.57 | -3.12 | -9.21 | -7.97 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | 1.86 | 2.76 | 1.19 | 2.34 | 1.51 | 2.68 | 0.56 | 2.22 |
| Quick Ratio | 1.86 | 1.86 | 2.76 | 1.15 | 2.27 | 1.41 | 2.58 | 0.53 | 2.06 |
| Cash Ratio | 1.09 | 1.09 | 1.83 | 0.79 | 1.89 | 1.13 | 1.93 | 0.23 | 1.32 |
| Asset Turnover | — | 1.01 | 0.73 | 0.50 | 0.41 | 0.72 | 0.38 | 0.59 | 0.52 |
| Inventory Turnover | — | — | — | 9.29 | 10.11 | 10.52 | 6.87 | 7.59 | 6.29 |
| Days Sales Outstanding | — | 37.27 | 44.03 | 57.10 | 48.38 | 24.48 | 122.61 | 78.67 | 33.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $8M | $6M | $4M | $2M | $1M | $5M | $46M | $1M |
Liquidity and dilution risk
Based on current market data, Biodesix trades at a price-to-sales multiple of 1.99, which suggests that investors are pricing in significant future revenue expansion despite the company's persistent lack of profitability and the inherent risks associated with its current cash-constrained operating model and reliance on external capital.
The 1.99x P/S multiple appears to discount the company's high gross margin profile while simultaneously acknowledging the substantial execution risk in reaching breakeven. Compared to peers like Veracyte, which commands a premium valuation, Biodesix's lower multiple may indicate that the market requires a higher risk premium for its smaller scale and more urgent need for capital.
According to historical financial data, Biodesix has struggled to generate positive returns on invested capital, with ROIC figures consistently remaining in negative territory, reaching -8.7% in 2026Q1, which underscores the difficulty of compounding value while the company continues to absorb heavy operating losses to fund its commercial expansion.
The persistent negative ROIC suggests that the capital deployed into laboratory infrastructure and sales force expansion has not yet reached the critical mass required to generate economic profit. Investors should monitor whether the recent shift toward higher-margin oncology diagnostics can eventually drive returns toward a positive trajectory as the business scales.
As reported in recent quarterly filings, the company's asset turnover ratio remains low at 0.28, reflecting the capital-intensive nature of its centralized laboratory model and the ongoing challenge of optimizing working capital efficiency while managing a complex revenue cycle across various private and public healthcare payers.
The variability in days sales outstanding, which fluctuated between 33 and 54 days over the last ten quarters, suggests that the company's cash conversion cycle is highly sensitive to reimbursement timing. This volatility in collections may exacerbate liquidity pressures, particularly when the company is simultaneously attempting to scale its diagnostic test volumes.
Based on the most recent balance sheet data, the company's debt-to-equity ratio of 7.84 in 2026Q1 indicates a highly leveraged position that significantly limits financial flexibility, especially given the company's ongoing reliance on external financing to bridge the gap between its current operating burn and future profitability.
The high debt-to-equity ratio, combined with negative interest coverage, suggests that the company's ability to service its obligations is heavily dependent on continued access to capital markets. This leverage profile warrants close monitoring, as any disruption in financing could force management to prioritize debt service over essential growth-oriented investments.
Investors frequently misapply the price-to-earnings ratio to Biodesix, which is fundamentally flawed given the company's negative earnings and the significant impact of non-cash stock-based compensation that obscures the true underlying cash burn and operational performance of this early-stage diagnostic business model.
Because the company is in a high-growth, pre-profit phase, the P/E ratio fails to capture the value of the underlying diagnostic IP and the potential for future operating leverage. Analysts should instead focus on metrics like EV/Sales or test volume growth, which better reflect the company's progress toward achieving the scale necessary for long-term profitability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BDSX stock.
Biodesix, Inc.'s current P/E ratio is -4.4x. This places it at the 50th percentile of its historical range.
Biodesix, Inc.'s return on equity (ROE) is -383.1%. The historical average is -279.5%.
Based on historical data, Biodesix, Inc. is trading at a P/E of -4.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Biodesix, Inc. has 75.2% gross margin and -31.5% operating margin.